COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01775618
Recruitment Status : Completed
First Posted : January 25, 2013
Last Update Posted : March 11, 2020
Information provided by (Responsible Party):

Brief Summary:

Hemophilia A is an inherited blood disorder in which one protein, Factor VIII, needed to form blood clots is missing or not present in sufficient levels. Hemophilia A causes the clotting process to be slowed and the person experiences bleeds causing serious problems that could lead to disability. The current standard treatment for severe hemophilia A is infusion of FVIII to stop bleeding, or regular scheduled treatment to prevent bleeds from occuring. Due to the short half-life of FVIII, prophylaxis may require treatment as often as every other day.

In this trial safety and efficacy of a long-acting recombinant Factor VIII molecule is being evaluated in 50 male subjects, < 12 years of age, with severe Hemophilia A. These subjects will receive open label treatment with long-acting rFVIII for approximately 6 months (or longer until 50 exposure days) on a regular schedule at least once every 7-days. Doses and dose intervals may be adapted to the subject's clinical need. A second group of patients will receive open label treatment with the same drug for 12 weeks on a regular schedule of 2x/week. Patients will attend the treatment center for routine blood samples and will be required to keep an electronic diary.

Subjects will be offered participation in an optional extension study to collect observations for at least an additional 50 exposure days.

Condition or disease Intervention/treatment Phase
Hemophilia A Biological: BAY94-9027 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 73 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A
Actual Study Start Date : May 29, 2013
Actual Primary Completion Date : March 19, 2015
Actual Study Completion Date : February 19, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemophilia

Arm Intervention/treatment
Experimental: BAY94-9027
Patients will receive BAY94-9027 intravenous prophylaxis injection in the main study.
Biological: BAY94-9027
Prophylaxis treatment 25-60 IU/kg at least 1x/week.

Experimental: Expansion group (Part 2)
Patients in expansion group will receive BAY94-9027 intravenous prophylaxis injection in study part 2 .
Biological: BAY94-9027
Prophylaxis treatment 25-60 IU/kg 2x/week for 12 weeks.

Primary Outcome Measures :
  1. Annualized number of all bleeds [ Time Frame: Up to 11 months ]
  2. Pharmacokinetics profile of BAY94-9027 based on blood concentration over the defined time period [ Time Frame: 6 time points from pre-infusion to 72 hours post-infusion ]
    Pharmacokinetics profile includes maximum concentration (Cmax), incremental recovery, mean residence time (MRT), apparent volume of distribution at steady state (Vss), half-life, area under the curve (AUC), and clearance, which are calculated values based on time-weighed blood concentration of drug.

  3. Response of acute bleeding events to treatment based on a 4-point scale (poor, moderate, good, or excellent) [ Time Frame: Up to 11 months ]
  4. Characterization of a potential immune response [ Time Frame: Up to 12 weeks ]

Secondary Outcome Measures :
  1. Inhibitor development after 10 to 15 exposure days (EDs) [ Time Frame: Up to 15 weeks ]
  2. Inhibitor development after 50 EDs [ Time Frame: Up to 11 months ]
  3. Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: Up to 11 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 12 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males < 12 years of age
  • Subjects with severe hemophilia A
  • Previously treated with FVIII for > 50 exposure days

Exclusion Criteria:

  • Subjects with current evidence of or history of inhibitors to FVIII
  • Any other inherited or acquired bleeding disorder
  • Platelet counts < 100,000/mm^3
  • Creatinine > 2x the upper limit of normal
  • Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) > 5x the upper limit of normal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01775618

Layout table for location information
United States, California
Sacramento, California, United States, 95817
United States, Florida
Pensacola, Florida, United States, 32504
United States, Ohio
Cincinnati, Ohio, United States, 45229
Cleveland, Ohio, United States, 44106-6007
Columbus, Ohio, United States, 43205-2696
United States, Pennsylvania
Hershey, Pennsylvania, United States, 17033
United States, Utah
Salt Lake City, Utah, United States, 84113
La Plata, Buenos Aires, Argentina, 1900
Wien, Austria, 1090
Gent, Belgium, 9000
Leuven, Belgium, 3000
Plovdiv, Bulgaria, 4002
Sofia, Bulgaria, 1527
Varna, Bulgaria, 9010
Canada, Alberta
Calgary, Alberta, Canada, T3B 6A8
Canada, Ontario
Toronto, Ontario, Canada, M5G 1X8
Thessaloniki, Greece, 54642
Ramat Gan, Israel, 5262000
Milano, Lombardia, Italy, 20122
Palermo, Sicilia, Italy, 90127
Padova, Veneto, Italy, 35128
Vilnius, Lithuania, 08661
Amsterdam, Netherlands
Utrecht, Netherlands, 3584 CX
New Zealand
Christchurch, New Zealand, 8011
Hamilton, New Zealand, 3204
Oslo, Norway, 0027
Lodz, Poland, 91-738
Olsztyn, Poland, 10-561
Bucharest, Romania, 011026
Bucharest, Romania, 022328
Timisoara, Romania, 300011
Esplugues de LLobregat, Barcelona, Spain, 08950
United Kingdom
Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE1 4LP
Bristol, United Kingdom, BS2 8AE
Manchester, United Kingdom, M13 9WL
Sheffield, United Kingdom, S10 2TH
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Additional Information:
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01775618    
Other Study ID Numbers: 15912
2012-004434-42 ( EudraCT Number )
First Posted: January 25, 2013    Key Record Dates
Last Update Posted: March 11, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Hemophilia A
Factor VIII
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII